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Abstract
Out-of-date or incomplete drug product labeling information may increase the risk of otherwise preventable adverse
drug events. In recognition of these concerns, the United States Federal Drug Administration (FDA) requires drug
product labels to include specific information. Unfortunately, several studies have found that drug product labeling
fails to keep current with the scientific literature. We present a novel approach to addressing this issue. The primary
goal of this novel approach is to better meet the information needs of persons who consult the drug product label for
information on a drug’s efficacy, effectiveness, and safety. Using FDA product label regulations as a guide, the
approach links drug claims present in drug information sources available on the Semantic Web with specific product
label sections. Here we report on pilot work that establishes the baseline performance characteristics of a
proof-of-concept system implementing the novel approach. Claims from three drug information sources were linked
to the Clinical Studies, Drug Interactions, and Clinical Pharmacology sections of the labels for drug products that contain
one of 29 psychotropic drugs. The resulting Linked Data set maps 409 efficacy/effectiveness study results, 784
drug-drug interactions, and 112 metabolic pathway assertions derived from three clinically-oriented drug information
sources (ClinicalTrials.gov, the National Drug File – Reference Terminology, and the Drug Interaction Knowledge Base)
to the sections of 1,102 product labels. Proof-of-concept web pages were created for all 1,102 drug product labels
that demonstrate one possible approach to presenting information that dynamically enhances drug product labeling.
We found that approximately one in five efficacy/effectiveness claims were relevant to the Clinical Studies section of a
psychotropic drug product, with most relevant claims providing new information. We also identified several cases
where all of the drug-drug interaction claims linked to the Drug Interactions section for a drug were potentially novel.
The baseline performance characteristics of the proof-of-concept will enable further technical and user-centered
research on robust methods for scaling the approach to themany thousands of product labels currently on themarket.
Keywords: Regulatory science, Drug information services, Drug labeling, Linked data, Scientific discourse ontologies,
Drug interactions, Pharmacokinetics, Treatment efficacy, Treatment effectiveness, Comparative effectiveness research
Introduction
The drug product label (also called “package insert”)
is a major source of information intended to help
clinicians prescribe drugs in a safe and effective man-
ner. Out-of-date or incomplete product label informa-
tion may increase the risk of otherwise preventable
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adverse drug events (ADEs). This is because many pre-
scribers and pharmacists refer to drug product labeling
for information that can help them make safe prescrib-
ing decisions [1,2]. A prescribing decision might be
negatively affected if the label fails to provide infor-
mation that is needed for safe dosing, or to prop-
erly manage (or avoid) the co-prescribing of drugs
known to interact. Prescribing decision-making might
also be indirectly affected if 1) the clinician depends
on third-party drug information sources, and 2) these
sources fail to add information that is available in
© 2013 Boyce et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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the scientific literature but not present in the product
label.
In recognition of these concerns, the US Federal Drug
Administration (FDA) Code of Federal Regulations (CFR)
Title 21 Part 201 Section 57 requires drug labels to
include specific information for FDA-approved drugs
[3]. Mandated information includes clinical studies that
support a drug’s efficacy for its approved indications,
known pharmacokinetic properties, clearance data for
special populations, and known clinically-relevant drug-
drug interactions. Unfortunately, for each of these types
of information, product labeling fails to keep current with
the scientific literature. For example:
• Marroum and Gobburu noted deficiencies in the
pharmacokinetic information provided by product
labels, especially for drugs approved in the 1980s [1],
• Boyce et al. found that the product label provided
quantitative data on age-related clearance reductions
for only four of the 13 antidepressants for which such
data was available [4],
• Steinmetz et al. found that quantitative information
on clearance changes in the elderly was present in
only 8% of 50 product inserts that they analyzed, [5],
and
• Hines et al. noted drug-drug interaction information
deficiencies in 15% of the product labels for drugs
that interact with the narrow therapeutic range drug
warfarin [6].
We present a novel approach to addressing prod-
uct labeling information limitations such as those listed
above. The primary goal of this novel approach is to bet-
ter meet the information needs of persons who consult
the drug product label for information on a drug’s efficacy,
effectiveness, and safety. The approach is based on the
hypothesis that a computable representation of the drug
effectiveness and safety claims present in product labels
and other high quality sources will enable novel methods
for drug information retrieval that do a better job of help-
ing drug experts, clinicians, and patients find complete
and current drug information than current search engines
and bibliographic databases.
Figure 1 is an overview of the system that we envi-
sion. Claims about drugs are currently present in sources
of drug information such as the drug product label,
studies and experiments published in the scientific lit-
erature, premarket studies and experiments reported in
FDA approval documents, and post-market data sources
such as drug effectiveness reviews and drug informa-
tion databases. Many of these sources are available, or
are becoming available, on the Semantic Web. Using
FDA product label regulations as a guide [3], a new
linked data set would be created that links claims present
in drug information sources available on the Seman-
tic Web to relevant product label sections. The linked
data set would create and automatically update claim-
evidence networks [7-11] to make transparent the moti-
vation behind specific claims. Customized views of the
linked dataset would be created for drug experts including
clinicians, researchers, and persons who maintain ter-
tiary drug information resources (i.e., proprietary drug
information products).
The objective of this paper is to report on our
pilot work that establishes the feasibility of the novel
approach and the baseline performance characteris-
tics of a proof-of-concept system. Because there is a
broad range of content written into product labels,
and the novel approach requires synthesizing research
from multiple areas of research, we have organized
this paper to report progress in three complementary
areas:
1. Linking relevant Semantic Web resources to the
product label: We describe a basic proof-of-concept
that demonstrates the Semantic Web technologies
and Linked Data principles [12,13] that we think are
necessary components of a full-scale system. The
proof-of-concept consists of a set of web pages
created using existing Semantic Web datasets, and
demonstrates one possible approach to presenting
information that dynamically enhances particular
product label sections.
2. First steps towards the automated extraction of
drug efficacy and effectiveness claims: Focusing on
drug efficacy and effectiveness studies registered with
ClinicalTrials.gov, we describe the methods and
baseline performance characteristics of a pilot
pipeline that automatically obtains claims from the
scientific literature and links it to the Clinical
Studies section of the product label for psychotropic
drugs.
3. A descriptive summary of challenges to the
automated claim extraction of metabolic pathways:
We provide a descriptive analysis of the challenges to
the automated identification of claims about a drug’s
metabolic pathways in full text scientific articles. The
analysis is based on manual identification of these
claims for a single psychotropic drug.
Results
Linking relevant semantic web resources to the product
label
Twenty-nine active ingredients used in psychotropic drug
products (i.e., antipsychotics, antidepressants, and seda-
tive/hypnotics) that were marketed in the United States at
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Figure 1 The general architecture of a system to provide dynamically enhanced views of drug product labeling using Semantic Web
technologies.
the time of this study were selected as the target for the
proof-of-concept.a These drugs were chosen because they
are very widely prescribed and a number of these “newer”
psychotropic drugs are involved in drug-drug interactions
[14]. Figure 2 shows the architecture of the proof-of-
concept system that we developed for these drugs. As the
figure shows, four data sources were used in the proof-
of-concept. One of the sources (DailyMed) contained the
text content of the three product label sections that were
the focus of this study (Clinical Studies, Drug Interactions,
and Clinical Pharmacology). The other three sources were
chosen because they contain rigorous scientific claims
that we expected to be relevant to pharmacists seeking
information about the efficacy, effectiveness, and safety
of a drug. These three resources, and the claims they
provided, were:
1. LinkedCT:b Drug efficacy and effectiveness studies
registered with ClinicalTrials.gov that have published
results (as indicated by an article indexed in
PubMed) [15,16]
2. National Drug File – Reference Terminology
(NDF-RT):c Drug-drug interactions listed as critical
or significant in the Veteran’s Administration
[17,18]
3. The Drug Interaction Knowledge Base (DIKB):d
Pharmacokinetic properties observed in
pharmacokinetic studies involving humans [19].
In order for the proof-of-concept to link claims from
these three sources to sections from the product labels
for the chosen drugs, we first implemented a Linked Data
representation of all product labels for the psychotropic
drugs used in our study. We constructed the Linked Data
set from the Structured Product Labels (SPLs) available
in the National Library of Medicine’s DailyMed resource.e
A total of 36,344 unique SPLs were transformed into an
RDF graph and loaded into an RDF store that provides a
SPARQL endpoint.f We refer to this resource as “Linked-
SPLs” throughout the remainder of this text. LinkedSPLs
contained product labels for all 29 psychotropic drugs in
this study.
We then created a separate RDF graph with map-
pings between product label sections and claims present
in the three drug information sources. This graph was
imported it into the same RDF store as LinkedSPLs. The
graph has a total of 209,698 triples and maps 409 effi-
cacy/effectiveness study results, 784 NDF-RT drug-drug
interactions, and 112 DIKB pathway claims to the sections
of 1,102 product labels.g Consideringmappings on a label-
by-label basis (see Listing 1), the graph has an average
of 50 mappings per product label (mean:50, median:50).
Twenty-four labels had the fewest number of mappings
(2), and two had greatest number of mappings (135).
Table 1 shows the counts for all mappings grouped by each
drug in the study. The next three sections provide more
detail on the specific mappings created for each product
label section.
Figure 2 The architecture of the proof-of-concept system described in this paper that demonstrates the dynamic enhancement of drug
product labels using Semantic Web technologies.
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Table 1 Counts of product labels and all linked claims
Drug Number of product labels Number of VANDFRT Number of DIKB inhibits/substrate ClinicalTrials.gov Published results
for products containing DDIs found for of assertions with evidence studies involving the from ClinicalTrials.gov
the drug the drug found for the drug drug studies involving the drug
Significant Critical Evidence for Evidence against
Antidepressants
Amitriptyline 57 16 8 0 0 1 1
Amoxapine 2 15 8 0 0 0 0
Bupropion 111 7 4 2 0 5 44
Citalopram 85 25 9 2* 4* 4 25
Desipramine 15 16 10 0 0 0 0
Doxepin 32 15 9 0 0 0 0
Duloxetine 17 26 8 3 4 4 4
Escitalopram 20 13 3 4* 5* 6 9
Fluoxetine 90 51 14 2 0 8 22
Imipramine 19 18 10 0 0 1 4
Mirtazapine 55 2 5 4 9 1 22
Nefazodone 5 39 20 3 6 0 0
Nortriptyline 29 16 11 0 0 3 24
Paroxetine 60 33 11 2 0 3 40
Selegiline 11 2 47 0 0 1 1
Sertraline 74 28 8 2 0 3 27
Tranylcypromine 2 3 61 0 0 3 71
Trazodone 38 8 10 1 0 2 2
Trimipramine 2 17 10 0 0 0 0
Venlafaxine 66 21 6 3 3 2 2
Antipsychotics
Aripiprazole 15 4 0 2 13 3 3
Clozapine 9 29 2 3 1 3 9
Olanzapine 42 0 1 1 0 5 13
Quetiapine 33 8 0 1 9 4 9
Risperidone 71 13 0 2 1 23 70
Ziprasidone 22 54 23 2* 9* 1 6
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Table 1 Counts of product labels and all linked claims (Continued)
Sedative Hypnotics
Eszopiclone 11 7 0 1 7 1 1
Zaleplon 24 0 0 1 1 0 0
Zolpidem 85 0 0 2 0 0 0
*Citalopram, escitalopram, and ziprasidone were each mapped to one claim for which there was both supporting and refuting evidence in the DIKB. Counts of product labels for each drug and claims that were linked to drug
product labeling from three Linked Data drug information sources.
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Listing 1 The total number of “claim” mappings present in
the proof-of-concept RDF graph by drug product label
PREFIX poc:<http://purl.org/net/nlprepository/dynamic-spl-enhancement-poc#>
SELECT ?spl COUNT(DISTINCT ?mapping) WHERE {
{
## mappings for the Clinical Studies section ##
poc:linkedct-result-map ?spl ?mapping.
?mapping poc:linkedct-result-drug ?drug.
} UNION {
## mappings for the Drug Interactions section ##
poc:ndfrt-ddi-map ?spl ?mapping.
?mapping poc:ndfrt-ddi-drug ?drug.
} UNION {
## mappings for the Clinical Pharmacology section ##
poc:dikb-pk-map ?spl ?mapping.
?mapping poc:dikb-pk-drug ?drug.
}}
GROUP BY ?spl
ORDER BY ?spl
Automatic linking of study abstracts from ClinicalTrials.gov
to the Clinical Studies section
The Clinical Studies section of the product label could be
mapped to the abstract of at least one published result for
22 of the 29 psychotropic drugs (76%) (see Table 1). Seven
drugs (24%) were not mapped to any published result. The
largest number of mappings was for risperidone, with 70
published results mapped to 71 product labels. There was
a considerable difference between the mean and median
number of published results that were mapped when such
a mapping was possible (mean: 19, median: 9).
Automatic linking of VANDF-RT drug-drug interactions to the
Drug Interactions section
The Drug Interactions section of the product label could
be mapped to at least one NDF-RT drug-drug interac-
tion for 27 of the 29 psychotropic drugs (93%). Table 1
shows the counts for all published result mappings for
each drug in the study. The number of mappings to drug-
drug interactions labeled “Significant” in the NDF-RT (see
Section “Methods” for explanation) ranged from 2 (mir-
tazapine and selegiline) to as many as 54 (ziprasidone)
with a mean of 19 and a median of 16. For “Critical” drug-
drug interactions, the number of mappings ranged from
one (olanzapine) to 61 (tranylcypromine) with a mean of
13 and median of 9.
Table 2 shows the counts and proportion of linked
drug-drug interaction claims that were noted as poten-
tially novel to the Drug Interaction section of at least one
antidepressant product label. For these drugs, a poten-
tially novel interaction was an NDF-RT interaction that
1) was not mentioned in the Drug Interaction section of
a product label based on a case-insensitive string match,
and 2) was not listed as an interacting drug based on our
review (prior to the study) of a single manually-reviewed
product label for the listed drug (see Section “Methods”
for further details). At least one potentially novel interac-
tion was linked to a product label for products containing
each of the 20 antidepressants. The largest number of
potentially novel “Significant” interactions was for nefa-
zodone and fluoxetine (31 and 28 respectively), while
tranylcypromine and selegiline had the largest number of
potentially novel “Critical” interactions (33 and 23 respec-
tively). All of the “Significant” drug interactions mapped
to seven antidepressants (35%) were novel, while all of
the “Critical” interactions mapped to five antidepressants
(25%) were novel. These results are exploratory and it is
not known how many of the potentially novel interactions
are truly novel.
Automatic linking ofmetabolic pathways claims from the
drug interaction knowledge base to the Clinical
Pharmacology section
The Clinical Pharmacology section of the product label
could be mapped to at least one metabolic pathway claim
for 20 of the 29 psychotropic drugs (69%). Table 1 shows
the counts for all pathway mappings for every drug in the
study stratified by whether the DIKB provided supporting
or refuting evidence for the mapped claim. Thirteen of the
20 drugs that were mapped to pathway claims with sup-
porting evidence were alsomapped to claims with refuting
evidence. In most cases, these mappings were to different
pathway claims, as only three drugs (citalopram, escitalo-
pram, and ziprasidone) were mapped to individual claims
with both supporting and refuting evidence. Three path-
way claims had both supporting and refuting evidence,
40 pathway claims had only supporting evidence, and 69
claims had only refuting evidence.
Generation of web pagemashups
The mappings described above were used to gener-
ate web pages that demonstrate one possible way that
users could be presented with information that dynam-
ically enhances product label sections. A total of 1,102
web pages were generated by the proof-of-concept using
a version of LinkedSPLs that was synchronized with
DailyMed content as of October 25, 2012. The web pages
are publicly viewable at http://purl.org/net/nlprepository/
outfiles-poc.h Figures 3, 4 and 5 show examples of the
web pages generated by the proof-of-concept for the three
sections we chose to focus on.
First steps towards the automated extraction of drug
efficacy and effectiveness claims
It is important to note that, for drug efficacy and
effectiveness claims, the proof-of-concept implements
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Table 2 Counts of potentially novel drug-drug interaction claims
Drug Number of VA-NDFRT DDIs Number of VA-NDFRT DDIs that were potentially novel
found for the drug to at least one product label. N ( % )
Significant Critical Significant Critical
Amitriptyline 16 8 8(50) 3 (38)
Amoxapine 15 8 11 (73) 4 (50)
Bupropion 7 4 5 (71) 3 (75)
Citalopram 25 9 5 (20) 4 (44)
Desipramine 16 10 16 (100) 6 (60)
Doxepin 15 9 15 (100) 9 (100)
Duloxetine 26 8 12 (46) 3 (38)
Escitalopram 13 3 3 (23) 1 (33)
Fluoxetine 51 14 28 (55) 8 (57)
Imipramine 18 10 18 (100) 6 (60)
Mirtazapine 2 5 1 (50) 1 (20)
Nefazodone 39 20 31 (80) 11 (55)
Nortriptyline 16 11 16 (100) 11 (100)
Paroxetine 33 11 15 (46) 5 (45
Selegiline 2 47 1 (50) 23 (49)
Sertraline 28 8 7 (25) 3 (38)
Tranylcypromine 3 61 1 (33) 33 (54)
Trazodone 8 10 8 (100) 10 (100)
Trimipramine 17 10 17 (100) 10 (100)
Venlafaxine 21 6 21 (100) 6 (100)
The number and proportion of VA NDF-RT drug-drug interactions that were noted as potentially novel to the Drug Interaction section of at least one antidepressant
product label. For these drugs, a potentially novel interaction was an NDF-RT interaction that was 1) not mentioned in the Drug Interaction section of a drug’s product
label based on a case-insensitive string match, and 2) not listed as an interacting drug based on our review (prior to the study) of a single manually-reviewed product
label the listed drug.
Figure 3 A Clinical Study section from an escitalopram product label as shown in the proof-of-concept. In this example, an efficacy claim is
being shown that was routed from the abstract of a published result for study registered in ClinicalTrials.gov.
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Figure 4 A Drug Interactions section from an escitalopram product label as shown in the proof-of-concept. In this example, several
“Significant” NDF-RT drug-drug interactions are being shown. The interaction marked as New to Section? was not found by manual inspection of a
single product label for an escitalopram drug product, nor by an automated case-insensitive string search of the Drug Interactions section of the
escitalopram product label.
only one of the two steps that are needed to imple-
ment a fully automated claim extraction process. While
the proof-of-concept retrieves text sources from which
drug efficacy and effectiveness claims can be extracted
(i.e., PubMed abstracts), these claims remain written in
unstructured text. We hypothesized that sentences con-
taining claims could be automatically extracted using a
pipeline that processed the text of the abstracts returned
from the LinkedCT query using an algorithm that auto-
matically identifies sentences stating conclusions. To test
the precision and recall of this approach, we first cre-
ated a reference standard of these conclusion claims for a
randomly chosen subset of psychotropic drugs. We then
evaluated a publicly-available system called SAPIENTA
[20] that can automatically identify conclusion sentences
in unstructured scientific text.
Development of a reference standard of relevant claims
Figure 6 shows the results of identifying relevant and novel
conclusion claims from efficacy and effectiveness stud-
ies routed to the Clinical Studies section via LinkedCT.
Table 3 lists results for each of the nine randomly-
selected psychotropic drugs. A total of 170 abstracts were
routed from PubMed to the Clinical Studies section of
Figure 5 A Clinical Pharmacology section from an escitalopram product label as shown in the proof-of-concept. In this example, an DIKB
metabolic pathway claim with supporting evidence is being shown.
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the products labels for the nine randomly sampled psy-
chotropics. Four of the abstracts were either not clinical
studies, or provided no other text content besides the title.
These were dropped from further analysis. Of the 166
remaining conclusions, two were not interpretable with-
out reading the full text article and 113 were judged to
not be relevant to a pharmacist viewing the Clinical Stud-
ies section. For the remaining 51 relevant conclusions,
the inter-rater agreement prior to reaching consensus was
0.69, reflecting “substantial” agreement according to the
criteria of Landis and Koch [21].
Twelve of the 51 relevant conclusions were judged
to apply to uses of the drug other than those for
which it was approved for by the FDA. Of the 39 rel-
evant conclusions that applied to an approved indica-
tion, 30 were judged to be novel to the Clinical Studies
section of at least one product label for a product con-
taining the drug. Inter-rater agreement prior to reach-
ing consensus on the novelty of these 30 relevant and
novel conclusions was also substantial with a Kappa of
0.72.
Determination of the precision and recall of an automated
extractionmethod
Figure 7 shows the results of determining the base-
line information retrieval performance of the proof-of-
concept system. SAPIENTA processed the same 170
abstracts mentioned in the previous section that were
routed from PubMed to the Clinical Studies section of
the product labels for the nine randomly sampled psy-
chotropics. Of the more than 2,000 sentences in the 170
abstracts, the program automatically classified 266 sen-
tences as Conclusions. In comparison, the conclusion
claims extracted manually from the abstracts consisted
of 318 sentences. Using these sentences as the reference
standard, the recall, precision, and balanced F-measure
for SAPIENTA was 0.63, 0.75, and 0.68 respectively. By
combining these results with the precision of routing Clin-
icalTrials.gov study results to the Clinical Studies section
via LinkedCT results in an overall “pipeline precision” of
0.23.
A descriptive summary of challenges to the automated
extraction of claims about a drug’s metabolic pathways
Although the proof-of-concept made links from claims
about a drug’s metabolic pathways present in the DIKB
resource to the Clinical Pharmacology section of the
product label, the DIKB has claims for only a small sub-
set (<100) of the thousands of drugs currently on the
market. To further investigate the feasibility of auto-
matically extracting claims about a drug’s pharmacoki-
netic properties, we manually traced the evidence for a
small number of claims pertaining to the pharmacoki-
netics of escitalopram that the proof-of-concept linked
from the DIKB to drug product labels. The goal of
this effort was to see if there were particular pat-
terns that we might use in future language analytics
systems.
We found that the inhibition and substrate claims are
derived from two texts, one describing a set of experi-
ments to deduce the metabolic properties (i.e., biotrans-
formation and enzyme inhibition) for escitalopram [22],
and one a product label produced by Forest Labs [23]. As
an example, there are two pieces of evidence against the
claim “escitalopram inhibits CYP2C19” – first, from the
Forest Labs text...
In vitro enzyme inhibition data did not reveal an
inhibitory effect of escitalopram on CYP3A4, -1A2,
-2C9, -2C19, and -2E1. Based on in vitro data,
escitalopram would be expected to have little
inhibitory effect on in vivo metabolism mediated by
these cytochromes.
...and second, from the Moltke et al. paper:
CYP2C19. R- and S-CT were very weak inhibitors,
with less than 50 percent inhibition of S-mephenytoin
hydroxylation even at 100micM. R- and S-DCT also
were weak inhibitors. R- and S-DDCT were moderate
inhibitors, with mean IC50 values of 18.7 and
12.1micM, respectively. Omeprazole was a strong
inhibitor of CYP2C19, as was the SSRI fluvoxamine
(see Table 2).
The claim “escitalopram is a substrate of CYP2C19” is
motivated by the following evidence in Moltke et al.:
At 10micM R- or S-CT, ketoconazole reduced reaction
velocity to 55 to 60 per cent of control, quinidine to 80
per cent of control, and omeprazole to 80 to 85 per
cent of control (Figure 6). When the R- and S-CT
concentration was increased to 100 M, the degree of
inhibition by ketoconazole increased, while inhibition
by quinidine decreased (Figure 6). These findings are
consistent with the data from heterologously expressed
CYP isoforms.
The validity of this claim depends on an assumption
(“omeprazole is an in vitro selective inhibitor of enzyme
CYP2C19”) which is a separate DIKB claim, supported by
a draft FDA guidance document [24].
The next claim is that escitalopram’s primary clearance
route is not by renal excretion and it is derived from the
following sentence in the Forest Laboratories text:
Following oral administrations of escitalopram, the
fraction of drug recovered in the urine as escitalopram
and S-demethylcitalopram (S-DCT) is about 8 per cent
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Figure 6 A flow diagram of the process and results of identifying relevant and novel conclusions from efficacy and effectiveness studies
routed to the product label Clinical Studies section via LinkedCT.
Table 3 Relevance and novelty of conclusion claims based onmanual validation
Drug ClinicalTrials.gov Published results from ClinicalTrials.gov
studies involving the drug studies involving the drug
N Relevant N ( % ) Novel (indication) Novel (off-label use)
Antidepressants
Citalopram 4 25 5 (20) 5
Duloxetine 4 4 4 (100) 3
Escitalopram 6 9 3 (33) 1 2
Mirtazapine 1 22 1 (5) 1 0
Nortriptyline 3 24 2 (8) 1 1
Venlafaxine 2 2 2 (100) 1 1
Antipsychotics
Olanzapine 5 13 7 (54) 6 1
Risperidone 23 70 26 (37) 21 5
Sedative Hypnotics
Eszopiclone 1 1 1 (100) 0 1
The relevance and novelty of conclusion claims linked from three Linked Data drug information sources to the product labeling for nine randomly selected
psychotropic drugs.
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and 10 per cent, respectively. The oral clearance of
escitalopram is 600 mL/min, with approximately 7 per
cent of that due to renal clearance.
The connection between the evidence and the claim
requires the domain knowledge that renal excretion is
roughly the same as the fraction of dose recovered in
urine.
Finally, the evidence for claims pertaining to escitalo-
pram’s metabolites again comes from the Forest Labs
text:
Escitalopram is metabolized to S-DCT and
S-didemethylcitalopram (S-DDCT).
From these examples, we ascertained four issues that
present major challenges for the automated extraction of
drug claims from a text source:
Self-referencing and anaphora. In narrative text,
coherence is often created by creating anaphoric
co-reference chains - where entities at other
locations in the text are referred to by pronouns
(it, they) and determiners (these, this). This makes
sentences such as these very easy for humans to read:
R-CT and its metabolites, studied using the same
procedures, had properties very similar to those of
the corresponding S-enantiomers.
However, automatically identifying the entities
referred by these referents “its metabolites”,
“the same procedures”, “similar properties”, and
“the corresponding S-enantiomers” is a non-trivial
task.
Use of ellipsis Often statements are presented in a
compact manner, where the full relations between
drugs and proteins are omitted, as in this
example:
Based on established index reactions, S-CT and
S-DCT were negligible inhibitors (IC50 > 100
μM) of CYP1A2, -2C9, -2C19, -2E1, and -3A, and
weakly inhibited CYP2D6 (IC50 = 70 - 80 μM)
A computational system would need to “unpack” this
statement to read the following list of relations (a
total of 12 statements).
• S-CT (escitalopram) was a negligible inhibitor
((IC50>100 μM) of CYP1A2
Figure 7 Determining the baseline information retrieval performance of the proof-of-concept system.
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• S-CT (escitalopram) was a negligible inhibitor
((IC50>100 μM) of CYP2C9
• ...
Domain knowledge is needed to be able to
resolve anaphora. The metabolites referred to in
the phrase “R-CT and its metabolites”, above, which
is referred to six times in the text, are not explicitly
described in the text. For even a human to be able to
define what they are it is necessary that they know
that the following sentence contains a definition of
the metabolites studied:
Transformation of escitalopram (S-CT), the
pharmacologically active S-enantiomer of
citalopram, to S-desmethyl-CT (S-DCT), and of
S-DCT to S-didesmethyl-CT (S-DDCT), was
studied in human liver microsomes and in
expressed cytochromes (CYPs).
Interestingly, this information is given only in the
abstract of the paper.
Key components are provided in other papers. As
with textual coherence, inter-textual coherence,
embedding the current text in the corpus of known
literature, is an important function of the text. In
certain cases key elements of the paper, such as the
methods, are entirely described through a reference,
e.g.:
Average relative in vivo abundances [... ] were
estimated using methods described in detail
previously (Crespi, 1995; Venkatakrishnan et al.,
1998 a,c, 1999, 2000, 2001; von Moltke et al., 1999
a,b; Störmer et al., 2000).
There is of course no way to ascertain what methods
were used without (computational) access to these
references; even so it might well not be obvious or
easy to identify the relevant methods in the
referenced texts.
Discussion
To the best of our knowledge, this is the first study
to demonstrate how claims about drug safety, efficacy,
and effectiveness present in Semantic Web resources
can be linked to the relevant sections of drug product
labels. While we focused on only three drug information
resources and a relatively small set of marketed drugs, the
resulting Linked Data set contains a considerable number
of claims that might help meet pharmacist information
needs. We emphasize that this was a pilot study and our
results are exploratory.
It is noteworthy that the labels for all 1,102 drug
products containing the drugs in our study could be linked
to at least one claim, and that, on average, 50 claims could
be linked to each product label. This suggests that there
are ample claims available on the Semantic Web that can
be linked to drug product labeling. One concern is that,
while the approach might do a good job of linking more
information with the product label, it might be poor at
providing the right kind of information. Our analysis of
a relatively simple automated approach that combines a
routing strategy with an existing scientific discourse anal-
ysis program (SAPIENTA) found that about one in five
efficacy/effectiveness conclusion claims would be relevant
to the Clinical Studies section of a psychotropic drug
product, the majority of which would provide the phar-
macist with new information about an indicated use of the
drug (Figure 6).
We also found evidence that if we performed this
endeavor at scale, many relevant and novel drug-drug
interaction claims would be found that could be linked
to the Drug Interactions section of the product label. At
least one potentially novel interaction was linked to all 20
antidepressants, and there were several cases where all
of the drug-drug interactions linked to the Drug Interac-
tions section for an antidepressant were potentially novel.
However, these results require further validation to ensure
that differences in how the drugs are referred to between
drug information sources, and between product labels, are
properly accounted for. For example, an NDF-RT inter-
action between digoxin and nefazodone was incorrectly
marked as potentially novel to nefazodone product labels
because the NDF-RT referred to digoxin by “digitalis”, a
broad synonym for drugs derived from foxglove plants
that are used to treat cardiac arrhythmias.
A manual inspection of potentially novel interactions
linked to several antidepressant product labels by co-
investigator JRH (a pharmacist and drug-interaction
expert) suggested that several of the linked interactions
would complement product label information. For exam-
ple, the NDF-RT interaction between escitalopram and
tapentadol was potentially novel to all 20 escitalopram
product labels. While no explanation for this NDF-RT
interaction is provided in the resource, it is possibly
based on the potential for tapentadol to interact in an
additive way with selective serotonin reuptake inhibitors
(SSRIs). This interaction might increase the risk of an
adverse event called “serotonin syndrome.” The labels
for all SSRIs appear to provide a generally-stated class
based interaction between SSRIs and other drug affect-
ing the serotonin neurotransmitter pathway. However,
one would have to know that tepentadol fits in this
category. Another example is the NDF-RT interaction
between metoclopramide and escitalopram. As with the
other example, this interaction was potentially novel to
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all escitalopram product labels and no explanation was
provided in the NDF-RT resource. The possible rea-
son that the NDF-RT notes the interaction is that esc-
italopram is a weak inhibitor of the Cytochrome P450
2D6 metabolic enzyme which is a potentially important
clearance pathway for metoclopramide. Thus, the drug
combination might increase the risk of metoclopramide
toxicity in some patients leading to adverse events such as
Tardive Dyskinesia.
Manual inspection also identified examples of poten-
tially novel NDF-RT interactions that might not be
mentioned in the label due to indeterminate evidence.
Three NDF-RT interactions involved amoxapine as an
object drug and rifampin, rifabutin, and rifapentine
as precipitant drugs. No explanation was accessible
from the NDF-RT resource and no clear mechanism
was apparent based on the drugs’ metabolic proper-
ties. For example, while rifampin is a known inducer
of certain Cytochrome P450s (especially Cytochrome
P450 3A4), we were unable to find evidence of an
induction interaction between rifampin and amoxap-
ine by searching a rifampin product label [25]. Sim-
ilarly, no results were returned from the PubMed
query RIFAMPIN AMOXAPINE INTERACTION. The
same was true for searches conducted for rifabutin
and rifapentine. Thus, while it is possible that these
interactions are missing from the product label, it is
also possible that insufficient evidence for the clini-
cal relevance of the interaction justifies their exclu-
sion.
The concern that drug-drug interactions are often
based on poor evidence (such as single case reports
or predictions) was raised at a recent multi-stakeholder
conference focusing on the drug-drug interaction evi-
dence base [26]. Another concern raised at the con-
ference was that there is currently no standard criteria
for evaluating the evidence for interactions. This leads
to considerable variation in the drug-drug interac-
tions listed across drug information sources [14]. In
future work we plan to develop methods that construct
more complete claim-evidence networks for drug-drug
interactions that go beyond establishing the potential
for the interaction [27], to also provide evidence of
the potential risk of harm in patients with specific
characteristics.
Inspection of the 113 non-relevant abstracts for pub-
lished results (see Figure 6) suggests that our approach
to identifying studies that were about a specific drug
returned many false positives. We think that this issue
is primarily due to how we linked the published results
from studies registered in ClinicalTrials.gov to the drugs
included in our study. In LinkedCT, entities tagged
in ClinicalTrials.gov as “interventions” for a study are
mapped to entities tagged as “drugs” in DrugBank using
a combination of semantic and syntactic matching that
has been shown to notably improve the linkage results
compared with matching by strings tokens alone [28].
However, many studies have multiple interventions. For
example, study NCT00015548 (The CATIE Alzheimer’s
Disease Trial)i lists three antispychotics and one antide-
pressant as interventions. As a result, the published results
for NCT00015548 that we linked to product labels for the
antidepressant drug (citalopram) included many results
that were actually about the effectiveness of one of the
antipsychotic drugs. Changing how we address this issue
should result in a significant improvement in the pipeline
precision of the automated system. One possibility would
be to exclude published results that do not mention
an indicated or off-label use of the drug (e.g., “depres-
sion” in the case of citalopram). Future work should
focus creating and validating a weighted combination of
such filters.
The manual analysis of metabolic pathway claims per-
taining to escitalopram found several factors that might
complicate automated extraction (complex anaphora, co-
reference, ellipsis, a requirement for domain knowledge,
and recourse to external documents via citations). These
offer some pointers to future work on automated extrac-
tion. However, it is also useful to consider how new inno-
vations in science publishing might enable the author of
a scientific paper to annotate a claim written into his/her
scientific article. To be feasible, this requires usable tools
and a set of simple standards that make annotation dur-
ing the publishing process efficient. Efforts along these
lines are currently being pioneered by groups such as the
Neuroscience Information Frameworkj.
We approached this proof-of-concept primarily think-
ing about a pharmacist’s information needs, but as
Figure 1 shows, there are other potential stakehold-
ers such as regulators, pharmacoepidemiologists, the
pharmaceutical industry, and designers of clinical deci-
sion support tools. The FDA has recently set challeng-
ing goals for advancing regulatory science [29] mak-
ing the agency a particularly important stakeholder for
future work. One regulatory science application of the
approach might be to identify possible quality issues
in drug product labels. For example, Listing 2 shows
a direct query for all NDF-RT drug interactions that
are potentially novel to the Drug Interactions section of
any bupropion product label. The result of this query
makes it evident that there are three NDF-RT interac-
tions (bupropion/carbamazepine, bupropion/phenelzine,
and bupropion/tamoxifen) that are potentially novel to
some bupropion product labels but not others. Assum-
ing that the interactions are truly novel (which is
not validated at this time), this finding might indicate
inconsistency across product labels that could require
further investigation.
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Listing 2 A query for all NDF-RT drug interactions that are
potentially novel to the Drug Interactions section of
bupropion product labels
PREFIX poc:<http://purl.org/net/nlprepository/dynamic-spl-enhancement-poc#>
SELECT ?label COUNT(DISTINCT ?spl) WHERE {
poc:ndfrt-ddi-map ?spl ?ddiMap.
?ddiMap poc:ndfrt-ddi-drug "bupropion".
?ddiMap poc:ndfrt-ddi-label ?label.
?ddiMap poc:ndfrt-ddi-severity ?severe.
OPTIONAL{?ddiMap poc:ndfrt-ddi-potentially-novel ?novel.}
FILTER (BOUND(?novel))
}
GROUP BY ?label
ORDER BY ?label
Doctors and patients might also benefit from dynam-
ically enhanced product label information. For example,
the proof-of-concept linked numerous NDF-RT drug-
drug interactions involving Ioflupane I-123 to the labels
for SSRI drugs. In all cases, these were marked as poten-
tially novel to the Drug Interactions section of the label.
Ioflupane I-123 is used to help radiologists test adult
patients for suspected Parkinsonian syndrome using a
brainscan. The concern here is that the SSRIs might alter
the ability of Ioflupane to bind to dopamine transporters,
possibly reducing the effectiveness of the brainscan [30].
Radiologists and patients, in addition to pharmacists,
might benefit from knowledge of this interaction. With
the current trend for participatory medicine, patients are
playing a greater role in their health and we think that
its important in future work to consider how the novel
approach could be used to help them avoid adverse drug
reactions by self monitoring (or monitoring for someone
whose care they manage).
Limitations
There are some potential limitations to this study.
While we evaluated the relevance and novelty of the
efficacy/effectiveness conclusion claims, our evaluation
included only a small number of randomly-selected drugs.
It is possible that the performance characteristics we
found for the nine psychotropics are not generalizable to
all psychotropic drug products, or to products containing
drugs from other classes. A similar potential limita-
tion exists for drug-drug interactions. Due to resource
limitations, we could only examine the potential novelty
of interactions linked to antidepressant drug products
and the results might be different for other drugs or drug
classes.
We linked claims from three information sources that
we expected to be relevant to pharmacists seeking infor-
mation about the efficacy, effectiveness, and safety of a
drug. However, the drug information sources we chose
might not be representative of all sources of drug claims
on the Semantic Web because we chose sources known to
be clinically oriented. Due to the hypothesis-driven nature
of basic and translational science, we expect that infor-
mation sources designed to support these user groups
might provide a smaller proportion of claims that would
be relevant to pharmacists and other clinicians. A scaled
approach may require labeling each included drug infor-
mation resource with meta-data describing its purpose
and construction. This would enable claims to be filtered
to meet the needs of various user groups.
Finally, the results of our evaluation of SAPIENTA
may have been influenced by how we defined conclusion
claims. The SAPIENTA system labels any given sentence
with one of 11 possible core scientific concept tags (of
which Conclusion is one), and so is designed to identify
all likely Conclusion sentences. However, the research
librarian who helped to produce the reference standard
extracted consecutive sentences that he judged were part
of a conclusions section, rather than attempting to identify
every sentence that reported a conclusion. Thus, some of
the SAPIENTA Conclusion sentences that were judged
to be false positives might have contained informative
conclusions. A similar issue is that our evaluation was per-
formed on abstracts rather than full text articles. While
SAPIENTAwas originally trained on full text articles from
a different scientific domain, its performance in this task
might have been influenced by the concise and structured
organization of biomedical abstracts. Future work should
examine the approach’s “pipeline precision” using full text
articles and a less section-based approach to defining
conclusion claims.
Related work
In recent years, the field of biological text mining has
focused on automatically extracting biomedical entities
and their relationships from both the scientific literature
and the product label. The goal of much of this work
has been to facilitate curation of biological knowledge
bases [31,32]. While it seems that very little research has
been directed toward the extraction of claims about a
drug’s effectiveness or efficacy, there has been a grow-
ing interest in the recognition of drug entities, and the
extraction of drug side-effects and interactions. With
respect to the dynamic enhancement of drug product
labeling, these methods can be divided into those that
1) identify claims present in product labeling and 2)
produce claims that may be linkable to the product
label.
Methods that identify claims present in product labeling
Duke et al. developed a program to extract adverse
events written into the product label that was found
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to have a recall of 92.8% and a precision of 95.1%
[33]. Comparable work by Kuhn et al. associated 1,400
side effect terms with more than 800 drugs [34]. In
previous work co-author RDB produced a manually-
annotated corpus of pharmacokinetic drug-drug inter-
actions and high-performance algorithm for extracting
drug-drug interactions from drug product labels [35].
The corpus was built by two annotators who reached
consensus on 592 pharmacokinetic drug-drug interac-
tions, 3,351 active ingredient mentions, 234 drug prod-
uct mentions, and 201 metabolite mentions present in
over 200 sections extracted from 64 drug product labels.
The drug interaction extraction algorithm achieved an
F-measure of 0.859 for the extraction of pharmacoki-
netic drug-drug interactions and 0.949 for determining if
the modality of the interactions (i.e., a positive interac-
tion or confirmation that no interaction exists). Efforts
on product labels outside of the United States include
Takarabe et al. who describe the automated extraction of
over 1.3 million drug-interactions from Japanese product
labels [36]. Also, Rubrichi and Quaglini reported excellent
performance (macro-averaged F-measure: 0.85 vs 0.81)
for a classifier they designed to assign drug-interaction
related semantic labels to text of the drug interaction
section of Italian “Summary of Product Characteristics”
documents [37].
Methods that produce claims thatmay be linkable to the
product label
Multiple translational researchers have produced new
algorithms for identifying drug-drug interactions and
metabolic pathways. Segura-Bedmar constructed a drug-
drug interaction corpus [38] consisting of documents
from DrugBank annotated with drug-drug interactions.
This corpus was the focus of ten research papers pre-
sented at the recent “Challenge Task on Drug-Drug Inter-
action Extraction” held at the 2011 SemEval Conference
[39]. The best performing system in this challenge
achieved an F-measure of 0.657 [40]. A second round
of this challenge is being held in 2013 with a corpus
expanded to include drug-drug interactions from MED-
LINE. Percha et al. built on work done by Coulet et al. [41]
on extracting and characterizing drug-gene interactions
from MEDLINE to to infer new drug-drug interactions
[42].
Recent work by Duke et al used a template based
approach to extract metabolic pathways from the sci-
entific literature, and then used the extracted metabolic
pathways to make drug-interaction predictions [43].
While similar to the work of Tari et al. [44], Duke et al.
went further by developing a pipeline for gathering phar-
macoepidemiologic evidence of the association of the
predicted drug interactions with specific adverse events.
Their approach of linking population data on the risk
of specific adverse events in patients exposed to specific
drug-drug interactions is groundbreaking, and has the
potential to address the challenge of knowing with any
confidence how risky a potential drug-drug interaction
will be for a particular patient population [26]. By linking
drug-drug interaction claims with data on exposure and
adverse events, clinicians may be better able to assess the
risk of allowing their patient to be exposed to a poten-
tial interaction. We would like to integrate this and similar
research in our future work on the dynamic enhance-
ment of the Drug Interactions section of the product
label.
Conclusions
We have demonstrated the feasibility of a novel approach
to addressing known limitations in the completeness and
currency of product labeling information on drug safety,
efficacy, and effectiveness. Our evaluation of a proof-of-
concept implementation of the novel approach suggests
that it is potentially effective. The baseline performance
characteristics of the proof-of-concept will enable further
technical and user-centered research on robust methods
for scaling the approach to themany thousands of product
labels currently on the market.
Methods
Linking relevant semantic web resources to the product
label
SPLs are documents written in a Health Level Seven stan-
dard called Structured Product Labeling that the FDA
requires industry to use when submitting drug prod-
uct label content [45]. More specifically, an SPL is an
XML document that specifically tags the content of each
product label section with a unique code from the Logi-
cal Observation Identifiers Names and Codes (LOINC)
vocabulary [46]. The SPLs for all drug products marketed
in the United States are available for download from the
National Library ofMedicine’s DailyMed resource [47]. At
the time of this writing, DailyMed provides access to more
than 36,000 prescription and over-the-counter product
labels.
The SPLs for all FDA-approved prescription drugs were
downloaded from the National Library of Medicine’s
DailyMed resource. We created an RDF version of the
data using a relational-to-RDF mapping approach. This
approach was chosen because it allows for rapid prototyp-
ing of RDF properties and tools are available that provide a
convenient method for publishing the data in human navi-
gable web pages. Custom scripts were written that load the
content of each SPL into a relational database. The rela-
tional database was then mapped to an RDF knowledge
base using the D2R relational to RDF mapper [48]. The
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mapping from the relational database to RDF was derived
semi-automatically and enhanced based on our design
goals, and a final RDF dataset was generated which is
hosted on a Virtuoso RDF serverk that provides a SPARQL
endpoint.
Listing 3 shows the SPARQL query used to retrieve
content from the Clinical Studies, Drug Interactions, and
Clinical Pharmacology sections of the product label data
for each psychotropic drug.
Listing 3 Queries for product label content andmetadata
present in the “LinkedSPLs” RDF graph
PREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>
PREFIX dailymed:<http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/>
PREFIX foaf: <http://xmlns.com/foaf/0.1/>
## Get metadata for the SPLs of all products containing a drug ##
SELECT ?label ?splId ?version ?setId ?org ?date ?homepage
WHERE {
?splId rdfs:label ?label.
?splId dailymed:subjectXref <%s>. ## The URI to the drug in DrugBank ##
?splId dailymed:versionNumber ?version.
?splId dailymed:setId ?setId.
?splId dailymed:representedOrganization ?org.
?splId dailymed:effectiveTime ?date.
?splId foaf:homepage ?homepage.
}
## Get the three sections of interest for a specific SPL ##
##(substituting an ?splid value from the above query for %s) ##
SELECT ?textClinicalStudies ?textDrugInteractions ?textClinicalPharmacology
WHERE {
OPTIONAL {<%s> dailymed:clinicalStudies ?textClinicalStudies }
OPTIONAL {<%s> dailymed:drugInteractions ?textDrugInteractions}
OPTIONAL {<%s> dailymed:clinicalPharmacology ?textClinicalPharmacology }
}
Automatic linking of study abstracts from ClinicalTrials.gov
to the Clinical Studies section
We wrote a custom Python scriptl that queried the
Linked Data representation of SPLs for the Clinical Stud-
ies sections of each of the drugs included in this study
(see Listing 4). For each returned section, the script
queried the LinkedCT SPARQL endpoint for clinical stud-
ies registered with ClinicalTrials.gov that were tagged in
LinkedCT as 1) related to the drug that was the active
ingredient of the product for which the section was writ-
ten, and 2) having at least one published result indexed
in PubMed. The former criterion was met for a study if
LinkedCT provided an RDF Schema seeAlso property
to DrugBank for the drug. The latter criterion was
met if LinkedCT had a trial_results_reference
property for the study. The result of this process was
a mapping from the meta-data for each published
result to the Clinical Studies section from a product
label.
Listing 4 LinkedCT Query for study results indexed in
PubMed
PREFIX rdfs: <http://www.w3.org/2000/01/rdf-schema#>
PREFIX linkedct: <http://data.linkedct.org/vocab/resource/>
SELECT ?trial, ?title, ?design, ?completion, ?reference
WHERE {
?trial a <http://data.linkedct.org/vocab/resource/trial>;
linkedct:trial_intervention ?inter;
linkedct:study_design ?design;
linkedct:official_title ?title;
linkedct:completion_date ?completion;
linkedct:trial_results_reference ?reference.
?inter rdfs:seeAlso <%s>. ## the URI to the drug in DrugBank ##
}
Automatic linking of VANDF-RT drug-drug interactions to the
Drug Interactions section
We extended the custom Python script to query the
Linked Data representation of SPLs for the Drug Interac-
tions sections of each of the drugs included in this study.
For each returned section, the script queried the Bio-
Portal SPARQL endpoint for drug-drug interactions in
the NDF-RT resource involving the drug that was identi-
fied as the active ingredient of the product for which the
section was written (see Listing 5). The NDF-RT labels the
drug-drug interactions that it provides “Critical” or “Sig-
nificant” reflecting judgment by members of the national
Veteran’s Administration (VA) formulary on the poten-
tial importance of the interaction [18]. Because they are
considered to have a greater potential for risk, those inter-
actions labeled “Critical” are less modifiable by local VA
formularies than interactions labeled “Significant.” The
script queried for interactions tagged with either label.
The result of this process was a mapping between the con-
tent of the Drug Interactions section from a product label
to a list of one or more NDF-RT drug-drug interactions.
Listing 5 BioPortal Query for NDF-RT drug-drug
interactions
PREFIX owl: <http://www.w3.org/2002/07/owl#>
PREFIX xsd: <http://www.w3.org/2001/XMLSchema#>
PREFIX rdfs:<http://www.w3.org/2000/01/rdf-schema#>
PREFIX skos:<http://www.w3.org/2004/02/skos/core#>
PREFIX ndfrt:<http://purl.bioontology.org/ontology/NDFRT/>
SELECT DISTINCT ?s ?label ?severity
FROM <http://bioportal.bioontology.org/ontologies/NDFRT>
WHERE {
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?s ndfrt:NDFRT_KIND ?o;
skos:prefLabel ?label;
ndfrt:SEVERITY ?severity. FILTER (regex(str(?o), “interaction”, “i”))
?s ndfrt:has_participant ?targetDrug.
?s ndfrt:STATUS “Active”∧∧xsd:string.
?targetDrug skos:prefLabel “%s”@EN. ## Preferred label for the drug in the
NDF-RT ##
}
The script was expanded to test how many NDF-
RT interactions might be novel to the Drug Interac-
tions section of each drug product label. A potentially
novel interaction was defined as an NDF-RT interac-
tion that was 1) not mentioned in the Drug Interaction
section of a product label based on a case-insensitive
string match, and 2) not listed in a reference set of
interactions created prior to the study as part of work
done for [4]. The reference set listed pharmacokinetic
and pharmacodynamic interactions derived by manu-
ally inspecting a single product label for each antide-
pressant drug. The reference set (Additional file 1:
Table S4) was created by two reviewers who were
both informaticists specializing in drug information.
Interactions involving drug classes were expanded to
include all drugs in the class using class assignments
in the NDF-RT terminology. The reference set did not
include interactions from antipsychotic or sedative hyp-
notic drug product labels. For these drugs, only the
first criterion mentioned above was used to identify a
potentially novel interaction.
Automatic linking ofmetabolic pathway claims from the
Drug Interaction Knowledge Base to the Clinical
Pharmacology section
We extended the custom Python script once more to
query the Linked Data representation of SPLs for the
Clinical Pharmacology sections of each of the drugs
included in this study. For each returned section,
the script queried the DIKB SPARQL endpoint for
claims about the pharmacokinetic drug properties of
the active ingredient of the product for which the
section was written (see Listing 6). The DIKB pro-
vides meta-data on the sources of evidence for each
claim and uses terms from the SWAN scientific dis-
course ontology [8] to label each evidence source
as one that either supports or refutes the claim.
The script queried for pharmacokinetic drug prop-
erty claims with either supporting or refuting evidence
sources. The result of this process was a mapping
between the content of the Clinical Pharmacology
section from a product label to a list of one or more
pharmacokinetic drug property claims and associated
evidence sources.
Listing 6 Queries to the DIKB for pharmacokinetic drug
property claims
PREFIX swanco: <http://purl.org/swan/1.2/swan-commons#>
PREFIX dikbD2R: <http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/>
## The enzymes that the drug is a substrate of ##
SELECT ?asrtId ?enz ?evFor ?evAgainst
WHERE {
?asrtId dikbD2R:object <%s>. ## Drug URI in the DIKB ##
?asrtId dikbD2R:slot dikbD2R:substrate_of.
?asrtId dikbD2R:value ?enz.
OPTIONAL {?asrtId swanco:citesAsSupportingEvidence ?evFor }
OPTIONAL {?asrtId swanco:citesAsRefutingEvidence ?evAgainst }
}
## The enzymes that the drug inhibits ##
SELECT ?asrtId ?enz ?evFor ?evAgainst
WHERE {
?asrtId dikbD2R:object <%s>. ## Drug URI in the DIKB ##
?asrtId dikbD2R:slot dikbD2R:inhibits.
?asrtId dikbD2R:value ?enz.
OPTIONAL {?asrtId swanco:citesAsSupportingEvidence ?evFor}
OPTIONAL {?asrtId swanco:citesAsRefutingEvidence ?evAgainst }
}
Generation of web pagemashups
The same Python script used to generate mappings was
extended to write a single web page for each drug product
that included the text content of three sections mentioned
above. A link was placed above each section that enabled
users to view the claims that had been mapped to that
section in a pop-up window. The pop-ups showing claims
linked to theDrug Interactions section provide a cue to the
user when the linked interactions were potentially novel
to the label (see above for further detail). Similarly, the
popups for claims linked to the Clinical Pharmacology
section cued the user when a specific metabolic path-
way claim may be novel to the product label based on a
simple string search of the text of the Clinical Pharma-
cology section for the metabolic enzyme reported in the
linked claim.
The Rialto Javascript widget library was used to gen-
erate the web pages and popups.m All code and data for
the proof-of-concept is archived at the Swat-4-med-safety
Google Code project.o
First steps towards the automated extraction of drug
efficacy and effectiveness claims
Development of a reference standard of relevant claims
Figure 6 provides a flow diagram of the process for iden-
tifying relevant and novel conclusions from efficacy and
effectiveness studies routed to the product label Clinical
Studies section via LinkedCT. Nine psychotropic drugs
were selected randomly from the 29 psychotropic drugs
used to create the proof-of-concept. Any study registered
in ClinicalTrials.gov that was associated with one of the
nine drugs in LinkedCT, and that had published results
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(see Listing 4), was included in the development of the ref-
erence standard. Abstracts for papers publishing results
from a study were retrieved from PubMed using the
PubMed identifier found in the URI values assigned to the
trial_results_reference property in the query
shown in Listing 4.
We then manually identified conclusions from each
abstract. A single research librarian with training in drug
information retrieval identified conclusions written into
the abstract. Abstracts describing clinical studies tend
to share a similar structure consisting of brief introduc-
tion, methods, conclusions, and results sections. There-
fore, the librarian extracted consecutive sentences that
he judged were part of a conclusions section rather than
attempting to annotate every sentence that reported a
conclusion.
Once these conclusion claims were manually extracted,
two reviewers (the librarian and co-author RDB) inde-
pendently determined which of them would be poten-
tially relevant to the Clinical Studies section of a product
label for each drug in our study. The criteria for “poten-
tially relevant” was based on the language of section
“(15)/14 Clinical studies” of CFR 201 which states that
this section of the label should describe at least one clin-
ical efficacy study for each labeled indication. Because
pharmacists would be the target users for the system
that we envision, we expanded the relevance criteria
to include:
1. any study involving a population different from the
average where it was shown that the drug should be
used slightly differently in order to be safe or
effective, and
2. efficacy or effectiveness studies for the off-label uses
mentioned in a widely-used drug information source
[49].
The reviewers made relevance judgements independently
and based only on information in the abstract. The agree-
ment of two reviewers over random chance (Kappa) was
calculated before the reviewers reached consensus on
a final set of relevant conclusions. Disagreements were
resolved by co-investigator JRH who is also a pharmacist.
The same pharmacist reviewed the consensus judgments
and noted if each potentially relevant conclusion refers to
the efficacy/effectiveness of the drug for an labeled indi-
cation, or an off-label use mentioned in a widely-used
drug information source [49]. Another round of review
was done by JRH and the research librarian focusing on
the novelty of relevant claims. These reviewers compared
each relevant conclusion with the text of the Clinical Stud-
ies section from a single product label for the intervention
drug. The label sections were sampled by convenience in
the first week of August 2012. As was done for relevance
judgements, Kappa was calculated before the reviewers
reached consensus on a final set of novel conclusions.
Finally, descriptive statistics and counts were derived for
the following:
• The number of potentially relevant conclusions
present in PubMed abstracts that could be routed via
ClinicalTrials.gov.
• The number of potentially relevant conclusions that
would be novel to the Clinical Studies section.
• The number of potentially relevant conclusions that
deal with off-label uses of a drug.
Determination of the precision and recall of an automated
extractionmethod
Figure 7 shows a flow diagram of the process we imple-
mented for determining the baseline information retrieval
performance of a fully automated extraction method that
could be implemented in the proof-of-concept system. A
publicly available online system called SAPIENTA [20]
was used to automatically annotate sentences in the same
text sources that were used to create the reference stan-
dard. The tool annotated each sentence with one of 11
core scientific concepts (Hypothesis, Motivation,
Background, Goal, Object, Method, Experiment,
Model, Result, Observation, Conclusion). The
system uses Conditional Random Field models [50]
that have been trained on 265 papers from chem-
istry and biochemistry, and makes classification deci-
sions according to a number of intra-sentential fea-
tures as well as features global to the document
structure.
The sentences automatically classified by SAPIENTA
as Conclusions were compared with the conclusions
manually-extracted by the research librarian to determine
the precision and recall of SAPIENTA for identifying con-
clusion sentences. We also calculated an overall “pipeline
precision” which combined the precision of the LinkedCT
queries for retrieving text sources from which drug effi-
cacy and effectiveness claims can be extracted with the
precision of SAPIENTA for automatically extracting con-
clusion sentences. “Pipeline recall” was not evaluated
because it would have required a systematic search for
articles relevant to the efficacy and effectiveness for
each study drug, something that was not feasible for
this study.
Endnotes
aThe 29 active ingredients used for this study were:
amitriptyline, amoxapine, aripiprazole, bupropion,
citalopram, clozapine, desipramine, doxepin, duloxe-
tine, escitalopram, eszopiclone, fluoxetine, imipramine,
mirtazapine, nefazodone, nortriptyline, olanzapine,
paroxetine, quetiapine, risperidone, selegiline, sertraline,
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tranylcypromine, trazodone, trimipramine, venlafaxine,
zaleplon, ziprasidone, and zolpidem.
bLinkedCTmaintained by co-author OH and is available
at http://linkedct.org/.
cThe NDF-RT is maintained by the Veteran’s Admin-
istration. A publicly available version of the resource is
present in the Bioportal at http://purl.bioontology.org/
ontology/NDFRT.
dCo-author RDB maintains the DIKB, it is accessible at
http://purl.org/net/drug-interaction-knowledge-base/.
eThe DailyMed website is located at http://dailymed.
nlm.nih.gov/dailymed/.
fSample product label data in LinkedSPLs can be viewed
at http://purl.org/net/linkedspls. The SPARQL endpoint
is at http://purl.org/net/linkedspls/sparql.
gThe graph has 161 metabolic pathway mappings but
49 are to the same claims with different evidence items.
Thus, there are 112 unique metabolic pathway claims.
hPlease note that the proof-of-concept web pages work
for Internet Explorer 7.0 and 8.0, Mozilla 5.0, Firefox ≥
2.0, and Google Chrome Version 22. They are known to
not work on Safari, Internet Explorer 9.0, and versions of
Internet Explorer (≤ 6.0).
iThis study is viewable in ClinicalTrials.gov at http://
clinicaltrials.gov/ct2/show/NCT00015548.
jThe home page for the Neuroscience Information
Framework is http://www.neuinfo.org/.
kWe use an Open Source version of Virtuoso http://
virtuoso.openlinksw.com/ available as an Ubuntu
package.
lThe exact script used for this study is located at https://
swat-4-med-safety.googlecode.com/svn/trunk/analyses/
pilot-study-of-potential-enhancements-07162012/
scripts.
mThe homepage for the Rialto project is http://rialto.
improve-technologies.com/wiki/.
oThe Swat-4-med-safety Google Code project is locate
at http://swat-4-med-safety.googlecode.com.
Additional file
Additional file 1: Table S4. The full list of drug-drug interactions (DDIs)
affecting drugs indicated for the treatment of depression. The list was
created based on a search conducted in the summer of 2011 using a
convenience sample of package inserts available at that time. One package
insert was retrieved for each of the included antidepressants. Whenever
possible, package inserts were retrieved from the Physician’s Desk
Reference (PDR). In cases where we could find no relevant package insert
in the PDR, one was retrieved from the National Library of Medicine’s
DailyMed website. RDB and RG identified statements referring to
pharmacokinetic DDIs and pharmacodynamic DDIs. Pharmacokinetic DDIs
needed to report a quantitative effect on AUC and/or Cl of an
antidepressant. All pharmacodynamic DDIs that could be identified from
package insert text were included.
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